In an effort to find new treatments for castrate-resistant prostate cancer, a TTUHSC research team led by Srinivas Nandana, ...

However, once they are altered (see below) to become oncogenes, their abnormal protein products exhibit increased activity that contributes to tumor growth. Therefore, instead of stopping within a ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

Northwestern Medicine scientists have discovered that inhibiting the GATA6 protein in mouse models ... is a global regulator and controls many key oncogenes in colon cancer," said Feng Yue ...

We had reviewer comments that said, ‘If it doesn’t encode for a protein, it doesn’t do anything. So why should we care?’” Diederichs says it took multiple attempts before his study was accepted for ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...